AU2020380968A1 - Treating liver disorders - Google Patents

Treating liver disorders Download PDF

Info

Publication number
AU2020380968A1
AU2020380968A1 AU2020380968A AU2020380968A AU2020380968A1 AU 2020380968 A1 AU2020380968 A1 AU 2020380968A1 AU 2020380968 A AU2020380968 A AU 2020380968A AU 2020380968 A AU2020380968 A AU 2020380968A AU 2020380968 A1 AU2020380968 A1 AU 2020380968A1
Authority
AU
Australia
Prior art keywords
compound
patient
liver
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020380968A
Other languages
English (en)
Inventor
Martijn Fenaux
Kevin Klucher
Yujin Wang
Weidong Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of AU2020380968A1 publication Critical patent/AU2020380968A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020380968A 2019-11-08 2020-11-06 Treating liver disorders Pending AU2020380968A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962933277P 2019-11-08 2019-11-08
US62/933,277 2019-11-08
US202063004403P 2020-04-02 2020-04-02
US63/004,403 2020-04-02
PCT/US2020/059522 WO2021092474A1 (fr) 2019-11-08 2020-11-06 Traitement de troubles hépatiques

Publications (1)

Publication Number Publication Date
AU2020380968A1 true AU2020380968A1 (en) 2022-05-12

Family

ID=75849579

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020380968A Pending AU2020380968A1 (en) 2019-11-08 2020-11-06 Treating liver disorders

Country Status (11)

Country Link
EP (1) EP4054567A4 (fr)
JP (1) JP2023501386A (fr)
KR (1) KR20220098168A (fr)
CN (1) CN114667142A (fr)
AU (1) AU2020380968A1 (fr)
BR (1) BR112022008639A2 (fr)
CA (1) CA3160445A1 (fr)
CL (1) CL2022001167A1 (fr)
IL (1) IL292459A (fr)
MX (1) MX2022005407A (fr)
WO (1) WO2021092474A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220184114A1 (en) 2020-12-14 2022-06-16 Regeneron Pharmaceuticals, Inc. Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
CA3019496A1 (fr) * 2016-03-28 2017-10-05 Intercept Pharmaceuticals, Inc. Medicament obtenu par combinaison d'un agoniste de fxr et d'arb
WO2018170173A1 (fr) * 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
US20210121493A1 (en) * 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
KR20210052507A (ko) * 2018-08-30 2021-05-10 테른스 파마슈티칼스, 인크. 간 장애 치료

Also Published As

Publication number Publication date
MX2022005407A (es) 2022-05-24
WO2021092474A1 (fr) 2021-05-14
EP4054567A4 (fr) 2024-01-10
JP2023501386A (ja) 2023-01-18
CL2022001167A1 (es) 2023-02-10
KR20220098168A (ko) 2022-07-11
EP4054567A1 (fr) 2022-09-14
BR112022008639A2 (pt) 2022-07-19
IL292459A (en) 2022-06-01
CA3160445A1 (fr) 2021-05-14
CN114667142A (zh) 2022-06-24

Similar Documents

Publication Publication Date Title
US20240000765A1 (en) Combination treatment of liver disorders
Davis Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics
US10940125B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
US20210379040A1 (en) Combination treatment of liver disorders
US20230181583A1 (en) Treating liver disorders with an ssao inhibitor
EP3743064B1 (fr) Traitement de la protéinurie
US20220387414A1 (en) Treating liver disorders
WO2021092474A1 (fr) Traitement de troubles hépatiques
WO2009047562A1 (fr) Procédés et compositions utilisés dans le traitement du prurit
WO2023220404A1 (fr) Traitement de stéatohépatite non-alcoolique
TW202327589A (zh) 肝病之組合療法
US20240316025A1 (en) Combination treatment of liver disorders
EP4166137A1 (fr) Agent thérapeutique pour la stéatose hépatique non alcoolique
EP4223291A1 (fr) Composition pour le traitement de maladies médiées par le canal kca3.1 comprenant un composé de phénylalkylcarbamate
Haddley Lu-AA-21004
EP1846105A2 (fr) Utilisation d'antagonistes alpha-2b pour le traitement de symptomes vasomoteurs